Scientists have uncovered a groundbreaking discovery that could transform how healthcare professionals understand irritable bowel syndrome (IBS), a common digestive disorder affecting over 10% of the global population. IBS often leads to recurring stomach pain, bloating, constipation, diarrhea, or a combination of these symptoms. Despite its prevalence, medical experts have yet to fully grasp why some individuals develop this condition, complicating efforts to develop universally effective treatments.
For years, the prevailing theory linked IBS primarily to disrupted communication between the brain and the gut. The digestive system is densely populated with millions of nerve cells that constantly exchange signals with the brain. Emotional factors like stress, anxiety, and mood disorders are known to worsen IBS symptoms, and many patients report that emotional stress exacerbates their digestive issues. Still, this explanation has never fully explained all cases of IBS.
A recent international study suggests a new piece of the puzzle: metabolism, especially how the body processes fats in the blood, may play a role in susceptibility to IBS. Led by Professor Mauro D’Amato of LUM University and CIC bioGUNE, the research was published in the journal Gut. This extensive genetic analysis is among the largest ever conducted on IBS, involving the genetic and health data of more than 2.7 million individuals from 22 major biobanks globally. The team compared the DNA of those with IBS against those without to pinpoint genetic factors associated with the condition.
The study identified 35 specific regions within the human genome linked to IBS. Some of these regions involved genes connected to the nervous system, reinforcing earlier findings. Unexpectedly, the research also uncovered a significant link with cardiometabolic health, particularly involving blood triglycerides—the fats that circulate in the bloodstream and store excess energy. Elevated triglyceride levels are already known to increase the risk of cardiovascular disease and fatty liver disease.
The strongest connection was found with a gene called GCKR, which plays a crucial role in how the liver manages sugar and fat. A particular variation in this gene was associated with higher triglyceride levels and an increased likelihood of developing IBS. These results suggest that alterations in liver metabolism might influence digestive health in ways previously unrecognized.
The study further explored existing medications that could potentially reverse the biological changes associated with IBS. Several drugs affecting fat metabolism and cardiovascular health emerged as promising candidates, indicating that some medications already available might be repurposed for IBS treatment after further testing.
This research broadens the understanding of IBS, highlighting that the condition may involve a complex interplay between the gut, brain, liver, and metabolic processes. The immense size of the study enhances confidence in the genetic findings, although it doesn’t establish a direct cause-and-effect relationship between high triglycerides and IBS. Clinical trials will be necessary before any new treatments are endorsed. Nonetheless, these findings pave the way for innovative research directions and could eventually lead to more personalized therapies for patients who don’t respond well to current options.
For additional insights into gut health, recent studies emphasize the vital connection between diet, immune function, and gut integrity. Notably, low-gluten, high-fiber diets have been shown to improve gut health and support weight management. Other research highlights how dietary choices, such as incorporating mycoprotein, may reduce the risk of bowel cancer and promote gut well-being.
Source: LUM University.









Source: TruthSocial
Created using Gemini


